Zsolt Hepp

1.9k total citations · 1 hit paper
54 papers, 1.3k citations indexed

About

Zsolt Hepp is a scholar working on Surgery, Epidemiology and Oncology. According to data from OpenAlex, Zsolt Hepp has authored 54 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Surgery, 19 papers in Epidemiology and 12 papers in Oncology. Recurrent topics in Zsolt Hepp's work include Bladder and Urothelial Cancer Treatments (30 papers), Urinary and Genital Oncology Studies (12 papers) and Multiple and Secondary Primary Cancers (11 papers). Zsolt Hepp is often cited by papers focused on Bladder and Urothelial Cancer Treatments (30 papers), Urinary and Genital Oncology Studies (12 papers) and Multiple and Secondary Primary Cancers (11 papers). Zsolt Hepp collaborates with scholars based in United States, United Kingdom and France. Zsolt Hepp's co-authors include Sepideh F. Varon, Emily Beth Devine, Ryan N. Hansen, Patrick Gillard, David W. Dodick, Lisa Bloudek, Jenny Chia, Ved V. Gossain, Ramon Espaillat and Maureen J. Lage and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Annals of Oncology.

In The Last Decade

Zsolt Hepp

51 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adherence to oral migraine-preventive medications among patients with chronic migraine

2014 323 citations Zsolt Hepp, Patrick Gillard et al. profile →

Peers

Countries citing papers authored by Zsolt Hepp

Since Specialization

Citations

This map shows the geographic impact of Zsolt Hepp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zsolt Hepp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zsolt Hepp more than expected).

Fields of papers citing papers by Zsolt Hepp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zsolt Hepp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zsolt Hepp. The network helps show where Zsolt Hepp may publish in the future.

Co-authorship network of co-authors of Zsolt Hepp

This figure shows the co-authorship network connecting the top 25 collaborators of Zsolt Hepp. A scholar is included among the top collaborators of Zsolt Hepp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zsolt Hepp. Zsolt Hepp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	REAL-WORLD ELIGIBILITY AND UTILIZATION OF AVELUMAB MAINTENANCE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA	Urologic Oncology Seminars and Original Investigations	Alicia K. Morgans, Guru Sonpavde et al.	0
2	Real-World Treatment Patterns and Clinical Outcomes in Patients With Locally Advanced or Metastatic Urothelial Carcinoma by Eligibility for Maintenance Avelumab	Clinical Genitourinary Cancer	Alicia K. Morgans, Phoebe Wright et al.	1
3	Understanding drivers of treatment preferences in locally advanced or metastatic urothelial carcinoma: A qualitative interview study with patients, caregivers, and physicians.	Journal of Clinical Oncology	Andrea B. Apolo, Nicholas I. Simon et al.	3
4	Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility	Urologic Oncology Seminars and Original Investigations	Alicia K. Morgans, Matthew D. Galsky et al.	12
5	Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC)	Current Oncology	Lisa Bloudek, Phoebe Wright et al.	8
6	Benchmarking Maintenance Therapy Survival in First-Line Platinum-Based Chemotherapy–Treated Patients with Advanced Urothelial Carcinoma Using Simulated Disease Modeling	Clinical Epidemiology	Matthew D. Galsky, Heidi S. Wirtz et al.	2
7	Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial	European Urology	Bradley A. McGregor, Peter H. O’Donnell et al.	20
8	Treatment with opioids in patients with locally advanced or metastatic urothelial carcinoma and matched non-cancer controls	Urologic Oncology Seminars and Original Investigations	Matthew D. Galsky, Simrun Grewal et al.	2
9	The direct and indirect economic burden of hypothyroidism in the United States: a retrospective claims database study	Journal of Medical Economics	Zsolt Hepp, Maureen J. Lage et al.	18
10	PCN118 Estimated Prevalence of Treated Locally Advanced or Metastatic Urothelial Carcinoma in Canada Using Simulation Modeling	Value in Health	Heidi S. Wirtz, Zsolt Hepp et al.	1
11	704P Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA	Annals of Oncology	Alicia K. Morgans, Matt D. Galsky et al.	6
12	Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysis	Urologic Oncology Seminars and Original Investigations	Alicia K. Morgans, Zsolt Hepp et al.	9
13	Levothyroxine Treatment of Pregnant Women with Hypothyroidism: Retrospective Analysis of a US Claims Database	Advances in Therapy	Maureen J. Lage, Zsolt Hepp et al.	10
14	PCN326 Qualitative Analysis of PAIN in Patients with Locally Advanced or Metastatic Urothelial Cancer	Value in Health	Zsolt Hepp, Alicia K. Morgans et al.	0
15	Hypothyroidism Treatment Among Older Adults: Evidence from a Claims Database	Advances in Therapy	Maureen J. Lage, Ramon Espaillat et al.	4
16	PCN108 - TARGETED LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN UROTHELIAL CARCINOMA	Value in Health	Andrew McGovern, Zsolt Hepp et al.	2
17	Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD)	CNS Drugs	Katelyn R. Keyloun, Ryan N. Hansen et al.	65
18	Cost Effectiveness of Onabotulinumtoxina Versus Ptns and Sns for the Treatment of Overactive Bladder from the US Payer Perspective	Value in Health	Zsolt Hepp, J. Lister et al.	2
19	Characterizing Health Care Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospective Claims Analysis	Value in Health	Zsolt Hepp, Beth Devine et al.	7
20	Cost-Effectiveness Of A Computerized Provider Order Entry System In Improving Medication Safety: A Case Study In Ambulatory Care	Value in Health	Zsolt Hepp, Sara Forrester et al.	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact